Du Jintong, Li Bei, Fang Yingli, Liu Yanguo, Wang Yang, Li Jisheng, Zhou Wen, Wang Xiuwen
Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China.
Shandong Cancer Hospital, Shandong Academy of Medical Science, Ji'nan, Shandong, 250012, China.
BMC Cancer. 2015 Jul 23;15:536. doi: 10.1186/s12885-015-1553-x.
Class III β-tubulin, Sox2, and Survivin play important roles in tumor survival and proliferation. However, the association of these three factors with clinicopathological characteristics, chemoresistance, and survival in patients with ovarian cancer remains controversial.
We investigated the predictive value and correlation among the expression levels of Class III β-tubulin, Sox2, and Survivin in 110 patients with stage III ovarian epithelial cancer, including 58 patients who received taxane-based chemotherapy and 52 patients who received non-taxane-based chemotherapy. Expression of these three factors was immunohistochemically examined in 110 ovarian tumor tissues obtained from patients before chemotherapy.
The positive expression rates for Class III β-tubulin, Sox2, and Survivin in ovarian tumor tissues were 59.09 %, 61.82 % and 52.73 %, respectively. The expression of nuclear Survivin and Class III β-tubulin was consistent with that of Sox2 (p = 0.005 and 0.020, respectively). Positive expression of Class III β-tubulin, Sox2, and nuclear Survivin was significantly associated with chemoresistance to taxane-based chemotherapy (p = 0.006, 0.007, and 0.009, respectively), but not to non-taxane-based chemotherapy. Additionally, overexpression of Class III β-tubulin, Sox2, and nuclear Survivin predicted poor progression-free survival in patients receiving taxane-based chemotherapy (p = 0.032, 0.005, and 0.004, respectively).
These findings suggest that overexpression of Class III β-tubulin, Sox2, and nuclear Survivin might be predictive of taxane resistance and poor progression-free survival in patients with stage III ovarian epithelial cancer. Expression of these three factors may show positive correlations in these patients.
Ⅲ类β-微管蛋白、Sox2和生存素在肿瘤存活和增殖中发挥重要作用。然而，这三种因子与卵巢癌患者临床病理特征、化疗耐药性及生存率之间的关联仍存在争议。
我们调查了110例Ⅲ期卵巢上皮癌患者中Ⅲ类β-微管蛋白、Sox2和生存素表达水平的预测价值及相关性，其中58例接受紫杉类化疗，52例接受非紫杉类化疗。在化疗前从患者获取的110份卵巢肿瘤组织中，采用免疫组化法检测这三种因子的表达。
卵巢肿瘤组织中Ⅲ类β-微管蛋白、Sox2和生存素的阳性表达率分别为59.09%、61.82%和52.73%。核生存素和Ⅲ类β-微管蛋白的表达与Sox2的表达一致（分别为p = 0.005和0.020）。Ⅲ类β-微管蛋白、Sox2和核生存素的阳性表达与紫杉类化疗耐药显著相关（分别为p = 0.006、0.007和0.009），但与非紫杉类化疗无关。此外，Ⅲ类β-微管蛋白、Sox2和核生存素的过表达预示接受紫杉类化疗患者的无进展生存期较差（分别为p = 0.032、0.005和0.004）。
这些发现表明，Ⅲ类β-微管蛋白、Sox2和核生存素的过表达可能预示Ⅲ期卵巢上皮癌患者对紫杉类耐药及无进展生存期较差。在这些患者中，这三种因子的表达可能呈正相关。
